Kian Pee Wan Capsules, 30-count bottles
Published August 19, 2026 · Recall initiated: March 21, 2026
Summary
FDA records drug Class I recall D-0769-2026, published August 19, 2026 and initiated March 21, 2026. Recalling firm: Buy-Herbal; Status: Ongoing; Reported quantity: 71 bottles; Lot: All lots within expiry. Class I means a reasonable probability of serious adverse health consequences or death.
Status when published: Ongoing — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.
What's the hazard
Marketed Without an Approved NDA/ANDA: Product contains undeclared drug ingredients dexamethasone and cyproheptadine.
What to do
Voluntary: Firm initiated · E-Mail
Get an email when a new FDA recall like this is published
Free. We only write when there's a new recall that matches. Unsubscribe in one click.
Recall details
- Manufacturer
- Buy-Herbal
- Distributor
- Product was sold to individual consumers via ebay third party seller.
- Lot
- All lots within expiry.
- Risk classification
- Class I
- Area (FDA)
- drug
- Country
- United States
Related recalls
- FDACLINDAMYCIN PALMITATE HYDROCHLORIDE FOR ORAL SOLUTION, USP, 75 mg/5 mL, Rx Only, 100 mL, Distributed by: AvetAugust 19, 2026
- FDAGlutathione (MDV), 200 mg/mL, 30 mL vial, each mL contains Glutathione 200 mg, Ascorbic Acid 20 mg, BenzylAugust 19, 2026
- FDACLEAR EYES Maximum Itchy Eye Relief, 0.5 fl oz (15 mL) per dropper bottle, Sterile, Dist. by Medtech ProductsAugust 19, 2026
- FDAOptiray Imaging Bulk Package-350, Ioversol Injection 74%, 350 mg/mL Organically Bound Iodine, 500 mLAugust 19, 2026
- FDASILDENAFIL CITRATE USP, 1.00KG, 1.00KG-bag Net Wt. Rx only " For Prescription Compounding Only", ShoolinAugust 19, 2026
- FDANhan Sam Tuyet Lien Truy Phong Hoan, Capsules, 30-Count Bottles, Manufactured by Yee Hong Pharmaceuticals,January 15, 2025
Questions about this recall
Was Kian Pee Wan Capsules, 30-count bottles recalled?
Yes. FDA published recall D-0769-2026 on August 19, 2026. Reported hazard: Marketed Without an Approved NDA/ANDA: Product contains undeclared drug ingredients dexamethasone and cyproheptadine.
What should I do if I have this product?
Voluntary: Firm initiated · E-Mail